Literature DB >> 17067552

Dominant negative pleiotrophin induces tetraploidy and aneuploidy in U87MG human glioblastoma cells.

Yunchao Chang1, James R Berenson, Zhaoyi Wang, Thomas F Deuel.   

Abstract

Pleiotrophin (PTN, Ptn) is an 18kDa secretory cytokine that is expressed in many human cancers, including glioblastoma. In previous experiments, interruption of the constitutive PTN signaling in human U87MG glioblastoma cells that inappropriately express endogenous Ptn reversed their rapid growth in vitro and their malignant phenotype in vivo. To seek a mechanism for the effect of the dominant-negative PTN, flow cytometry was used to compare the profiles of U87MG cells and four clones of U87MG cells that express the dominant-negative PTN (U87MG/PTN1-40 cells); here, we report that the dominant-negative PTN in U87MG cells induces tetraploidy and aneuploidy and arrests the tetraploid and aneuploid cells in the G1 phase of the cell cycle. The data suggest that PTN signaling may have a critical role in chromosomal segregation and cell cycle progression; the data suggest induction of tetraploidy and aneuploidy in U87MG glioblastoma cells may be an important mechanism that contributes to the loss of the malignant phenotype of U87MG cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17067552      PMCID: PMC1850963          DOI: 10.1016/j.bbrc.2006.09.148

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

1.  Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta.

Authors:  K Meng; A Rodriguez-Peña; T Dimitrov; W Chen; M Yamin; M Noda; T F Deuel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

Review 2.  Pleiotrophin: a cytokine with diverse functions and a novel signaling pathway.

Authors:  Thomas F Deuel; Nan Zhang; Hsui-Jen Yeh; Inmaculada Silos-Santiago; Zhao-Yi Wang
Journal:  Arch Biochem Biophys       Date:  2002-01-15       Impact factor: 4.013

3.  A novel 17 kD heparin-binding growth factor (HBGF-8) in bovine uterus: purification and N-terminal amino acid sequence.

Authors:  P G Milner; Y S Li; R M Hoffman; C M Kodner; N R Siegel; T F Deuel
Journal:  Biochem Biophys Res Commun       Date:  1989-12-29       Impact factor: 3.575

4.  Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity.

Authors:  Y S Li; P G Milner; A K Chauhan; M A Watson; R M Hoffman; C M Kodner; J Milbrandt; T F Deuel
Journal:  Science       Date:  1990-12-21       Impact factor: 47.728

5.  Significance of the expression of the growth factor pleiotrophin in pancreatic cancer patients.

Authors:  Hans-Jürgen Klomp; Oliver Zernial; Sabine Flachmann; Anton Wellstein; Hartmut Juhl
Journal:  Clin Cancer Res       Date:  2002-03       Impact factor: 12.531

6.  Pleiotrophin disrupts calcium-dependent homophilic cell-cell adhesion and initiates an epithelial-mesenchymal transition.

Authors:  P Perez-Pinera; S Alcantara; T Dimitrov; J A Vega; T F Deuel
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-10       Impact factor: 11.205

7.  Model for the genetic evolution of human solid tumors.

Authors:  S E Shackney; C A Smith; B W Miller; D R Burholt; K Murtha; H R Giles; D M Ketterer; A A Pollice
Journal:  Cancer Res       Date:  1989-06-15       Impact factor: 12.701

Review 8.  HBNF and MK, members of a novel gene family of heparin-binding proteins with potential roles in embryogenesis and brain function.

Authors:  P Böhlen; I Kovesdi
Journal:  Prog Growth Factor Res       Date:  1991

9.  An 18-kd heparin-binding protein of developing brain that is distinct from fibroblast growth factors.

Authors:  H Rauvala
Journal:  EMBO J       Date:  1989-10       Impact factor: 11.598

10.  Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients.

Authors:  R Jäger; B List; C Knabbe; B Souttou; D Raulais; T Zeiler; A Wellstein; A Aigner; A Neubauer; G Zugmaier
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

View more
  5 in total

1.  Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor.

Authors:  D C Stylianou; A Auf der Maur; D P Kodack; R T Henke; S Hohn; J A Toretsky; A T Riegel; A Wellstein
Journal:  Oncogene       Date:  2009-07-27       Impact factor: 9.867

2.  Intratumoral patterns of clonal evolution in gliomas.

Authors:  Ana Luísa Vital; Maria Dolores Tabernero; Inês Crespo; Olinda Rebelo; Hermínio Tão; Fernando Gomes; Maria Celeste Lopes; Alberto Orfao
Journal:  Neurogenetics       Date:  2009-09-17       Impact factor: 2.660

3.  Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology.

Authors:  Ana Luísa Vital; Maria Dolores Tabernero; Abel Castrillo; Olinda Rebelo; Hermínio Tão; Fernando Gomes; Ana Belen Nieto; Catarina Resende Oliveira; Maria Celeste Lopes; Alberto Orfao
Journal:  Neuro Oncol       Date:  2010-05-18       Impact factor: 12.300

4.  Pleiotrophin expression and role in physiological angiogenesis in vivo: potential involvement of nucleolin.

Authors:  Marina Koutsioumpa; Georgia Drosou; Constantinos Mikelis; Katerina Theochari; Dionussios Vourtsis; Panagiotis Katsoris; Efstathia Giannopoulou; Jose Courty; Christos Petrou; Vassiliki Magafa; Paul Cordopatis; Evangelia Papadimitriou
Journal:  Vasc Cell       Date:  2012-03-16

5.  ALK receptor activation, ligands and therapeutic targeting in glioblastoma and in other cancers.

Authors:  Anton Wellstein
Journal:  Front Oncol       Date:  2012-12-19       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.